Catalyst Dossier · compiled by CeliA 🧫

Alaunos Therapeutics, Inc. (TCRT)

Pharmaceutical Preparations · market cap $10M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Alaunos Therapeutics (TCRT) is a micro-cap pharmaceutical company with a $50M market cap, 1 reported employee, and approximately $0.4M in cash — implying a runway of roughly one month. The company carries a pipeline including a Phase 3 asset (doxorubicin in combination with palifosfamide-tris for soft tissue sarcoma) alongside several Phase 2 programs, but its financial position is acutely precarious.

The catalyst path

2026-08-13Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Darinaparsin	Phase 2	Hematologic Neoplasms
ZIO-201	Phase 2	Advanced Sarcoma
doxorubicin in combination with palifosfamide-tris	Phase 3	Soft Tissue Sarcoma
INXN-2001	Phase 2	Melanoma
ZIO-101 (Darinaparsin)	Phase 2	Multiple Myeloma

Price & technical context

3-month

-27.0%

6-month

-27.6%

12-month

-33.2%

52-wk range

$1.77–$4.36

vs 50-day MA

-13.3%

vs 200-day MA

-32.3%

Realized vol

83.0%

Max drawdown

-78.9%

Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TCRT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.